Evidence map›Paper›PMID 22528514›Full record

ArticleMedical oncology (Northwood, London, England)2012

Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma.

Marco K C Hui, Kenneth K Y Lai, Kwok Wah Chan, John M Luk, Nikki P Lee, Yvonne Chung, Leo C M Cheung, Gopesh Srivastava, Sai Wah Tsao, Johnny C Tang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Marco K C HuiDepartment of Surgery, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong, China.
Kenneth K Y Lai
Kwok Wah Chan
John M Luk
Nikki P Lee
Yvonne Chung
Leo C M Cheung
Gopesh Srivastava
Sai Wah Tsao
Johnny C Tang
Simon Law
University of Hong Kong · HKHong Kong Polytechnic University · HKQueen Mary Hospital · CNRoche (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To examine the correlation of survivin (both total and nuclear survivin) with clinicopathological parameters of esophageal squamous cell carcinoma (ESCC) patients. Tumors and non-tumor tissues near the proximal resection margins were resected from ESCC patients undergone esophagectomy. Quantitative polymerase chain reaction (qPCR) was performed to detect survivin mRNA expression level in the 10 paired tumor and adjacent non-tumor tissues. To confirm with the clinical situation, survivin mRNA and protein expression were measured by qPCR and immunoblot, respectively, in 5 ESCC cell lines and a non-neoplastic esophageal epithelial cell line. Immunohistochemistry was employed to reveal the cellular localization of survivin in tumor tissues isolated from the 64 ESCC patients undergone surgery alone. Up-regulation of survivin mRNA and protein was found in 5 ESCC lines (HKESC-1, HKESC-2, HKESC-3, HKESC-4, and SLMT-1) when compared to a non-neoplastic esophageal epithelial cell line NE-1. In particular, HKESC-3, HKESC-4, and SLMT-1 cells demonstrated ~50-fold increase in survivin mRNA. High level of survivin mRNA in tumor tissues when compared to non-tumor tissues was found in 70 % (7 of 10) of clinical cases. The increase in expression ranged from ~twofold to ~16-fold. Immunohistochemistry results showed that survivin was found at the cell nuclei in all specimens examined. Nuclear expression of survivin was inversely associated with the likelihood of developing nodal metastasis (p = 0.021) and significantly associated with early-stage ESCC (p = 0.039). Nuclear survivin could serve as a marker for indicating disease status in ESCC patients.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellCell NucleusEsophageal NeoplasmsFemaleHumansImmunoblottingImmunohistochemistryInhibitor of Apoptosis ProteinsMaleMiddle AgedReverse Transcriptase Polymerase Chain ReactionSurvivinBiomarkers, TumorBIRC5 protein, humanInhibitor of Apoptosis ProteinsSurvivin

Identifiers

PMID22528514
PMCPMC3505527
OpenAlexW2068546655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.